MedTrace Logo

Peng Block or Suprascapular Nerve Block for Postoperative Analgesia in Shoulder Artroscopy ?

NCT05666076 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2025-06-11

No results posted yet for this study

Summary

Arthroscopic shoulder surgery, which has been frequently applied in recent years, provides long-term positive clinical results and increases the quality of life after surgery, while it can cause severe pain in the early postoperative period. Postoperative pain management is very important in shoulder arthroplasty. Adequate pain control; mental state, nutrition, cost of care, rehabilitation, and patient satisfaction, are of great importance for the patients' recovery and contribute to a successful surgical outcome.

In this study, the investigators aimed to compare the effects of suprascapular nerve block and shoulder pericapsular nerve block, which will be performed preoperatively with ultrasound, on the level of postoperative pain in patients who will undergo shoulder arthroscopy surgery under general anesthesia.

Conditions

  • Orthopedic Disorder
  • Shoulder Pain
  • Surgery
  • Analgesia

Interventions

PROCEDURE

Pericapsular nerve block

The investigators will perform a pericapsular nerve block on that patient group for postoperative analgesia in shoulder arthroscopy.

PROCEDURE

Suprascapular nerve block

The investigators will perform a suprascapular nerve block on that patient group for postoperative analgesia in shoulder arthroscopy.

DRUG

Bupivacaine Hydrochloride

The investigators will perform a pericapsular nerve block on that patient group for postoperative analgesia with bupivacaine hydrochloride

DRUG

Bupivacaine Hydrochloride

The investigators will perform a suprascapular nerve block on that patient group for postoperative analgesia with bupivacaine hydrochloride

Sponsors & Collaborators

  • Bakirkoy Dr. Sadi Konuk Research and Training Hospital

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-02
Primary Completion
2024-04-17
Completion
2024-04-29

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05666076 on ClinicalTrials.gov